Long-term intraperitoneal deferoxamine for hemochromatosis.
Intraperitoneal deferoxamine is a well established treatment for aluminum accumulation syndrome in patients with end-stage renal disease receiving peritoneal dialysis, but the use of intraperitoneal deferoxamine has not been described outside of the setting of chronic renal failure. We present here a case of secondary hemochromatosis, complicated by cirrhosis and cardiomyopathy, in which a chronic peritoneal dialysis catheter was used both to treat ascites and to deliver parenteral deferoxamine for iron overload. Daily urinary iron excretion was similar to that achieved when using standard routes of deferoxamine administration. Over a 2-year period, reversal of both the biochemical indicators and the clinical manifestations of iron overload was accomplished.
Swartz
R D
RD
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109-0364, USA.
Legault
D J
DJ
D000328:Adult; D009202:Cardiomyopathies / Q000150:complications; D003676:Deferoxamine / Q000008:administration & dosage*; D005260:Female; D006432:Hemochromatosis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007274:Injections, Intraperitoneal / Q000295:instrumentation; D008103:Liver Cirrhosis / Q000150:complications; D017262:Siderophores / Q000008:administration & dosage*
D017262:Siderophores; D003676:Deferoxamine